Louisiana Medicaid spending on GLP-1 drugs

How much did Louisiana Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $230.9 million for GLP-1 drugs paid through Louisiana Medicaid in 2025, across at least 230,359 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 63 rows of 229, so these figures are floors.

Pharmacies were reimbursed at least $44.6 million for GLP-1 drugs paid through Louisiana Medicaid in 2026 (quarter 1 only, as posted so far), across at least 42,742 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 27 rows of 71, so these figures are floors.

By year and ingredient

2020at least $3,661,689No data$27,134,702at least $7,830,010at least $8,395,774No dataat least $357,249$170,872at least $47,550,296
2021at least $8,011,581No data$29,316,069at least $32,213,823at least $4,543,329Suppressed$502,416$165,483at least $74,752,700
2022at least $31,820,534at least $2,603,884at least $21,882,763at least $85,750,055at least $1,652,472No data$480,872$106,647at least $144,297,228
2023at least $141,530,487at least $44,707,338at least $12,290,000at least $86,310,839at least $619,431No dataat least $435,052at least $14,403at least $285,907,550
2024at least $145,280,667at least $84,088,372at least $2,562,612$36,720,684at least $180,291No data$270,955at least $15,251at least $269,118,832
2025at least $104,145,069at least $108,225,414at least $510,652at least $17,875,497at least $21,739No dataat least $167,897Suppressedat least $230,946,267
2026 (Q1)at least $18,932,359at least $22,890,639at least $25,541at least $2,738,720SuppressedNo data$28,403Suppressedat least $44,615,662

By product, 2025

Ozempicat least $97,843,000at least 101,0633 of 27
Rybelsusat least $3,605,442at least 3,63612 of 24
Wegovyat least $2,696,627at least 2,0741 of 21
Mounjaroat least $108,108,221at least 103,4425 of 52
Zepboundat least $117,193at least 1109 of 11
Liraglutide (generic name listing)at least $435,731at least 92812 of 33
SaxendaSuppressedSuppressed1 of 1
Victozaat least $74,922at least 1196 of 10
Trulicityat least $17,875,497at least 18,7183 of 34
Bydureonat least $21,739at least 271 of 2
ByettaSuppressedSuppressed2 of 2
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliquaat least $167,897at least 2421 of 5
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $55,030,245at least 54,78615 of 56
Q2 2025at least $58,877,761at least 59,59011 of 53
Q3 2025at least $60,469,050at least 60,00315 of 56
Q4 2025at least $56,569,210at least 55,98022 of 64

By quarter, 2026 (posted so far)

Q1 2026at least $44,615,662at least 42,74227 of 71

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.